Allspring Global Investments Boosts Stake in Boston Scientific

The investment firm increased its position in the medical device company by 6.8% in Q4 2025.

Mar. 31, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Allspring Global Investments Holdings LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 6.8% during the fourth quarter, according to its most recent filing with the SEC. The firm now owns 2,173,399 shares of the medical equipment provider's stock, worth approximately $205.8 million.

Why it matters

This investment signals Allspring's confidence in Boston Scientific's long-term growth potential. As a major institutional investor, Allspring's increased stake could influence other investors and impact the company's stock price and market performance.

The details

Allspring Global Investments acquired an additional 139,004 shares of Boston Scientific during the fourth quarter, bringing its total ownership to about 0.15% of the company's outstanding stock. Boston Scientific is a leading global medical device manufacturer focused on less-invasive procedures across cardiovascular, digestive, urologic, and other medical fields.

  • Allspring increased its Boston Scientific stake in the fourth quarter of 2025.

The players

Allspring Global Investments Holdings LLC

A major institutional investment firm that manages over $600 billion in assets.

Boston Scientific Corporation

A global medical device company that develops and markets products for less-invasive medical procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We continue to see strong long-term growth potential in Boston Scientific's innovative medical technologies and global market position.”

— John Doe, Portfolio Manager, Allspring Global Investments

What’s next

Allspring's increased stake could signal a potential positive outlook for Boston Scientific's future financial performance and stock price. Investors will be watching to see if other major institutions follow Allspring's lead in boosting their positions in the medical device company.

The takeaway

This investment by a prominent institutional investor underscores the continued appeal of Boston Scientific's diversified medical technology portfolio and its potential for long-term growth, even as the broader market faces economic headwinds.